CoChat

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing

Open access
Slavin, Thomas P., Banks, Kimberly C., Chudova, Darya, Oxnard, Geoffrey R., Odegaard, Justin I., Nagy, Rebecca J., Tsang, Kar Wing Kevin, Neuhausen, Susan L., Gray, Stacy W., Cristofanilli, Massimo, Rodriguez, Angel A., Bardia, Aditya, Leyland-Jones, Brian, Janicek, Mike F., Lilly, Michael, Sonpavde, Guru, Lee, Christine E., Lanman, Richard B., Meric-Bernstam, Funda, Kurzrock, Razelle, Weitzel, Jeffrey N. · 2018 · Journal of Clinical Oncology
Cited by 115

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Purpose: To determine the potential for detection of incidental germline cancer predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent solid tumor somatic mutation evaluation. Patients and Methods: Data were evaluated from 10,888 unselected patients with advanced (stage III/IV) cancer who underwent Guardant360 testing between November 2015 and December 2016. The main outcome was prevalence of putative germline mutations identified among 16 actionable hereditary cancer predisposition genes. Results: More than 50 cancer types were studied, including lung (41%), breast (19%), colorectal (8%), prostate (6%), pancreatic (3%), and ovarian (2%). Average patient age was 63.5 years (range, 18 to 95 years); 43% were male. One hundred and fifty-six individuals (1.4%) had suspected hereditary cancer mutations in 11 genes. Putative germline mutations were more frequent in individuals younger than 50 years versus those 50 years and older (3.0% v 1.2%, respectively; P < .001). Highest yields of putative germline findings were in patients with ovarian (8.13%), prostate (3.46%), pancreatic (3.34%), and breast (2.2%) cancer. Putative germline mutation identification was consistent among 12 individuals with multiple samples. Patients with circulating tumor DNA copy number variation and/or reversion mutations suggestive of functional loss of the wild-type allele in the tumor DNA also are described. Conclusion: Detection of putative germline mutations from cfDNA is feasible across multiple genes and cancer types without prior mutation knowledge. Many mutations were found in cancers without clear guidelines for hereditary cancer genetic counseling/testing. Given the clinical significance of identifying hereditary cancer predisposition for patients and their families as well as targetable germline alterations such as in BRCA1 or BRCA2, research on the best way to validate and return potential germline results from cfDNA analysis to clinicians and patients is needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.00328

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 115

Metadata

Authors
Slavin, T. P., Banks, K. C., Chudova, D., Oxnard, G. R., Odegaard, J. I., Nagy, R. J., Tsang, K. W. K., Neuhausen, S. L., Gray, S. W., Cristofanilli, M., Rodriguez, A. A., Bardia, A., Leyland-Jones, B., Janicek, M. F., Lilly, M., Sonpavde, G., Lee, C. E., Lanman, R. B., Meric-Bernstam, F., Kurzrock, R., & Weitzel, J. N.
Venue
Journal of Clinical Oncology
Published
2018-12-10
Volume
36
Issue
35
Pages
3459-3465
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2896098340
Cited by
115
References
8
FWCI
6.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. https://app.cochat.ai/papers/10.1200/jco.18.00328
The paper
Slavin, T. P., Banks, K. C., Chudova, D., Oxnard, G. R., Odegaard, J. I., Nagy, R. J., Tsang, K. W. K., Neuhausen, S. L., Gray, S. W., Cristofanilli, M., Rodriguez, A. A., Bardia, A., Leyland-Jones, B., Janicek, M. F., Lilly, M., Sonpavde, G., Lee, C. E., Lanman, R. B., Meric-Bernstam, F., . . . Weitzel, J. N. (2018). Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.00328

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.